Home Blog of Signal Transduction ER stress & UPR JNK The roles of physiological and synthetic IAP antagonism on c-IAP1/2 degradation

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

The roles of physiological and synthetic IAP antagonism on c-IAP1/2 degradation

 

The inhibitor of apoptosis proteins (IAP) play critical roles in variety cellular signaling pathways related to immune and inflammatory responses. Among the family members cellular inhibitor of apoptosis protein 1 and 2 (c-IAP1/2) are key regulators of NF-κB, which can induce degradation of c-IAP1/2 while activating. This non-canonical NF-κB pathway is activated by a limited subset of the tumor necrosis factor (TNF) receptor superfamily, including CD30, CD40 and TNFR2. Kocab et al. took a system approach to extensively compare the transcriptional programs triggered by CD30, which can degrade c-IAPs to SM-164, a synthetic IAP antagonist induces c-IAP degradation. The article was published in Oncogene.

 

Researchers used a technique called Bru-seq, which allows the specific analysis of newly transcribed RNA, for identification of gene expression profiles following each stimulus. Analysis of the profiles of CD30 activation and SM-164 treatment revealed differences between these two modes of IAP antagonism, indicating novel functions and consequences of c-IAP1/2 degradation, which was the downregulated expression of genes related to the ribosome and translation. The findings provide insight into the mechanism of SMs, as well as our understanding of their therapeutic potential. 

 

Reference:
Oncogene. 2015 Feb 9. doi: 10.1038/onc.2015.3.

Related Products

Cat.No. Product Name Information
S1460 SP600125 SP600125 (Nsc75890) is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc. SP600125 is also a broad‐spectrum inhibitor of serine/threonine kinases including Aurora kinase A，FLT3 and TRKA with of IC50 of 60 nM, 90 nM and 70 nM. SP600125 inhibits autophagy and activates apoptosis.

Related Targets

JNK